Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ghadimi

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
International Journal of Colorectal Disease|March 21, 2012
Bilobar spreading of colorectal liver metastases does not significantly affect survival after R0 resection in the era of interdisciplinary multimodal treatmentK Homayounfar, A Bleckmann, L C Conradi, et al.
British Journal of Cancer|March 25, 2023
Combined regression score predicts outcome after neoadjuvant treatment of oesophageal cancerA I Damanakis, F Gebauer, A Stapper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2018
Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trialR-D Hofheinz, D Arnold, E Fokas, et al.
Genes, Chromosomes & Cancer|November 24, 1999
Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell linesT Knutsen, V K Rao, T Ried, et al.
Cancer Research|November 24, 2001
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesisJ L Phillips, S W Hayward, Y Wang, et al.
ESMO Open|February 22, 2025
Corrigendum to "mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)": [ESMO Open 9 (2024) 103703]R-D Hofheinz, F Herrle, T Dechow, et al.
ESMO Open|September 11, 2024
mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214)R-D Hofheinz, F Herrle, T Dechow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2018
Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trialE Fokas, R Fietkau, A Hartmann, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2020
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final resultsM Sinn, T Liersch, H Riess, et al.
BMC Cancer|October 24, 2019
Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trialU A Wittel, D Lubgan, M Ghadimi, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
International Journal of Colorectal Disease|March 21, 2012
Bilobar spreading of colorectal liver metastases does not significantly affect survival after R0 resection in the era of interdisciplinary multimodal treatmentK Homayounfar, A Bleckmann, L C Conradi, et al.
British Journal of Cancer|March 25, 2023
Combined regression score predicts outcome after neoadjuvant treatment of oesophageal cancerA I Damanakis, F Gebauer, A Stapper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2018
Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trialR-D Hofheinz, D Arnold, E Fokas, et al.
Genes, Chromosomes & Cancer|November 24, 1999
Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell linesT Knutsen, V K Rao, T Ried, et al.
Cancer Research|November 24, 2001
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesisJ L Phillips, S W Hayward, Y Wang, et al.
ESMO Open|February 22, 2025
Corrigendum to "mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)": [ESMO Open 9 (2024) 103703]R-D Hofheinz, F Herrle, T Dechow, et al.
ESMO Open|September 11, 2024
mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214)R-D Hofheinz, F Herrle, T Dechow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2018
Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trialE Fokas, R Fietkau, A Hartmann, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2020
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final resultsM Sinn, T Liersch, H Riess, et al.
BMC Cancer|October 24, 2019
Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trialU A Wittel, D Lubgan, M Ghadimi, et al.
Pageof 8